Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsRory Shallis, MD
Assistant Professor AdjunctDownloadHi-Res Photo
About
Copy Link
Titles
Assistant Professor Adjunct
Biography
Dr. Shallis received his MD from Rutgers-Robert Wood Johnson Medical School, completed his residency training at Brown University-Rhode Island Hospital and fellowship training at Yale-New Haven Hospital.
He is focused on the care and research of patients with myeloid malignancies, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). He also participated in the K12 Calabresi Immuno-Oncology Training Program and currently participates as an investigator in several clinical trials aimed at improving the outcomes of patients with AML and MDS.
Dr. Shallis also maintains research interest in epidemiological, outcomes and effectiveness research as it pertains to the hematologic malignancies with a goal of identifying barriers to effective care and ultimately strategies to improve the outcomes of patients with these malignant diseases. Dr. Shallis conducts research with the Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center at Yale University.
Dr. Shallis has presented his research at multiple regional, national and international meetings and is a member of the National Comprehensive Cancer Network (NCCN) clinical guidelines for MDS and AML panels. He is an author on more than 75 peer-reviewed publications and book chapters, most of which as first author and has served as an ad hoc reviewer for many journals including Leukemia, Haematologica, Blood Advances, Leukemia Research, Leukemia & Lymphoma, Acta Haematologica, Hematology, Therapeutic Advances in Hematology, Expert Review of Hematology, BMC Hematology, eJHaem and Future Oncology among others.
Last Updated on November 17, 2022.
Appointments
Medical Oncology and Hematology
Assistant Professor AdjunctPrimary
Other Departments & Organizations
- All Institutions
- Developmental Therapeutics
- Leukemia & Lymphoma Program
- Medical Oncology and Hematology
Education & Training
- Fellowship
- Yale - New Haven Hospital (2020)
- Internship
- Brown University - Rhode Island Hospital (2017)
- Residency
- Brown University - Rhode Island Hospital (2017)
- MD
- Rutgers University - Robert Wood Johnson Medical School (2014)
- BA
- Rutgers College, Cell Biology & Neuroscience Psychology (2010)
Research
Copy Link
Overview
Medical Research Interests
Epidemiology; Leukemia; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Myeloproliferative Disorders
ORCID
0000-0002-8542-2944
Research at a Glance
Yale Co-Authors
Frequent collaborators of Rory Shallis's published research.
Publications Timeline
A big-picture view of Rory Shallis's research output by year.
Research Interests
Research topics Rory Shallis is interested in exploring.
Jan Philipp Bewersdorf, MD, FACP
Amer Zeidan, MBBS, MD
Nikolai Podoltsev, MD, PhD
Maximilian Stahl, MD
Lourdes Mendez, MD, PhD
Rong Wang, PhD
183Publications
3,194Citations
Myelodysplastic Syndromes
Myeloproliferative Disorders
Leukemia
Myelodysplastic-Myeloproliferative Diseases
Publications
2026
Mechanistic overview and suggested strategies to overcome BCL-2 inhibitor resistance in TP53-mutated acute myeloid leukemia
Iqbal U, Shallis R. Mechanistic overview and suggested strategies to overcome BCL-2 inhibitor resistance in TP53-mutated acute myeloid leukemia. Frontiers In Cell And Developmental Biology 2026, 14: 1779094. DOI: 10.3389/fcell.2026.1779094.Peer-Reviewed Original ResearchConceptsTP53-mutated acute myeloid leukemiaAcute myeloid leukemiaBcl-2Executioner phase of apoptosisUpregulation of fatty acid metabolismBcl-2 familyBCL-2 dependencePhase of apoptosisMyeloid leukemiaInhibitor resistanceFamily gene mutationsBcl-2 inhibitorsFatty acid metabolismAssociated with higher ratesPopulation of patientsGenomic instabilityVenetoclax combinationsPleotropic functionsOverall survivalAcid metabolismTreatment landscapeMolecular subsetsMarrow microenvironmentLineage plasticityClinical outcomesPrognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents.
Drekolias D, Tuz Zahra F, Fileni C, Sallman D, Mo Q, Chan O, Zhang L, Vincelette N, Yu X, Sammut R, Moon J, Park J, Umasangtongkul S, Lledo F, Razabdouski T, Cheng C, Qin D, Mai K, Ball S, Shallis R, Xie Z, Kuykendall A, Padron E, Sweet K, Walker A, Komrokji R, Lancet J, Niyongere S, Cluzeau T, Yun S. Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents. Blood Cancer Discovery 2026, of1-of11. PMID: 41671569, PMCID: PMC12967238, DOI: 10.1158/2643-3230.bcd-25-0193.Peer-Reviewed Original ResearchAltmetricConceptsAcute myeloid leukemiaHypomethylating agentsOverall survivalMyeloid leukemiaPrognostic modelHigh-risk groupPersonalized risk stratificationDel(7q)/-7MECOM rearrangementMedian OSInferior OSIntensive chemotherapyCytogenetic profileIDH1/2 mutationsPrognostic separationRisk stratificationC-indexMultivariate analysisVenetoclaxLeukemiaPatientsHypomethylationExternal validationMutationsChemotherapyHypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities.
Boussi L, Bewersdorf J, Liu Y, Shallis R, Aguirre L, Bystrom R, Zucenka A, Garciaz S, DeAngelo D, Stone R, Luskin M, Garcia J, Winer E, Chen E, Wadleigh M, Berton G, Ling K, Zeidan A, Stein E, Shimony S, Goldberg A, Stahl M. Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities. Haematologica 2026 PMID: 41609030, DOI: 10.3324/haematol.2025.288891.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaIntensive chemotherapyOverall survivalMultivariate analysisAllo-SCTComplete remissionMyeloid leukemiaRandomized trialsPredictors of long-term survivalAllogeneic stem cell transplantationAssociated with inferior survivalHigh risk of relapseHigh riskStem cell transplantationRisk of relapseCohort of patientsLong-term survivalFrontline treatment approachesMonosomal karyotypeInduction chemotherapyFrontline therapyComplex karyotypeHypomethylating agentsInferior survivalMyeloid diseasesComparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics
Aguirre L, Bewersdorf J, Liu Y, Shallis R, Boussi L, Zucenka A, Garciaz S, Bystrom R, DeAngelo D, Stone R, Luskin M, Garcia J, Winer E, Ling K, Chen E, Wadleigh M, Berton G, Stein E, Goldberg A, Mendez L, Zeidan A, Sallman D, Shimony S, Stahl M. Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics. Blood Neoplasia 2026, 3: 100201. PMID: 41859348, PMCID: PMC12997325, DOI: 10.1016/j.bneo.2026.100201.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaComposite complete remissionHigh-risk cytogeneticsIntensive chemotherapyMonosomal karyotypeComplex karyotypeOverall survivalFrontline regimenFrontline therapyAllogeneic hematopoietic stem cell transplantationHematopoietic stem cell transplantationOptimal frontline therapyMedian overall survivalAssociated with OSStem cell transplantationFrontline optionInferior OSComplete remissionHypomethylating agentsOS differenceCell transplantationSurvival outcomesMyeloid leukemiaCompare remissionCytogenetic featuresMenin Inhibition in Acute Myeloid Leukemia: Pathobiology, Progress and Promise
Joshi U, Shallis R. Menin Inhibition in Acute Myeloid Leukemia: Pathobiology, Progress and Promise. Biomedicines 2026, 14: 219. PMID: 41595753, PMCID: PMC12838656, DOI: 10.3390/biomedicines14010219.Peer-Reviewed Original ResearchCitationsConceptsAcute myeloid leukemiaMyeloid leukemiaMenin inhibitorsMolecular mechanisms of leukemogenesisMolecular mechanismsPhase 3 studyMechanisms of leukemogenesisTranscription factor HOXA9Variable patient outcomesRare lesionsAggressive malignancyTreatment paradigmSafety profileMalignant transformationEpigenetic regulationGenetic anomaliesProtein meninMenin inhibitionClinical landscapePatient outcomesTherapeutic agentsDrug approvalMeninBiological diversityLeukemiaMarrow Microenvironmental Pathobiology and Therapeutic Opportunities for TP53-Mutated Myelodysplastic Syndrome/Acute Myeloid Leukemia
Hunter C, Im A, Shallis R. Marrow Microenvironmental Pathobiology and Therapeutic Opportunities for TP53-Mutated Myelodysplastic Syndrome/Acute Myeloid Leukemia. Cancers 2026, 18: 275. PMID: 41595195, PMCID: PMC12838703, DOI: 10.3390/cancers18020275.Peer-Reviewed Original ResearchCitationsAltmetricConceptsBone marrow microenvironmentAcute myeloid leukemiaMyelodysplastic syndromeTP53Marrow microenvironmentTumor microenvironmentMyeloid leukemiaMyelodysplastic syndrome/acute myeloid leukemiaMyeloid-derived suppressor cellsImmune regulating cellsMechanisms of chemoresistanceAberrant tumor microenvironmentRepair protein recruitmentUpregulation of cytokinesSignal transduction pathwaysCell cycle arrestProfound immunosuppressionHypomethylating agentsSuppressor cellsMyeloid neoplasmsCell surface receptorsUnique pathophysiologyBone marrowCell therapyLeukemic cellsMenin inhibitors for adult acute myeloid leukemia: 2025 update
Iqbal U, Fadul J, Sallman D, Shallis R. Menin inhibitors for adult acute myeloid leukemia: 2025 update. Expert Opinion On Investigational Drugs 2026, 35: 37-48. PMID: 41474933, DOI: 10.1080/13543784.2025.2612321.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsAcute myeloid leukemiaMenin inhibitorsMyeloid leukemiaAdult acute myeloid leukemiaQT interval prolongationSupportive care needsFrontline optionRelapsed/refractory settingPseudo-progressionInterval prolongationDismal outcomeDifferentiation syndromeLeukemic cell differentiationClinical dataDrug classesWeb of Science databasesCare needsMedical Subject HeadingsPatient benefitLiterature searchMeninUnmet needsCell differentiationLeukemiaInhibitors
2025
CO60 Comparative Real-World Effectiveness of Tyrosine Kinase Inhibitors as Induction Therapy for Philadelphia-Positive Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study
Badar T, Heckman M, Zhang Y, Blumenfeld S, Narra R, Curran E, Kota V, Shallis R, Patel A, Advani A, Palmisiano N, Atallah E, Mims A, Coltoff A, Hunter C, Patel S, DuVall A, Omer Z, Jamy O, Jonas B, Foucar C, Reddick L, Hernandez L, Litzow M. CO60 Comparative Real-World Effectiveness of Tyrosine Kinase Inhibitors as Induction Therapy for Philadelphia-Positive Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study. Value In Health 2025, 28: s53. DOI: 10.1016/j.jval.2025.09.162.Peer-Reviewed Original ResearchIsavuconazole provides effective and tolerable antifungal prophylaxis for patients with acute myeloid leukemia
Hunter C, Chou A, Roeder H, Eighmy W, Bewersdorf J, Mendez L, Stahl M, Podoltsev N, Zeidan A, Shallis R. Isavuconazole provides effective and tolerable antifungal prophylaxis for patients with acute myeloid leukemia. Leukemia Research 2025, 160: 108144. PMID: 41365214, DOI: 10.1016/j.leukres.2025.108144.Peer-Reviewed Original ResearchAltmetricConceptsInvasive fungal infectionsAcute myeloid leukemiaDrug-drug interactionsSide effect profileOverall survivalTransaminase elevationVisual disturbancesMyeloid leukemiaAntifungal prophylactic agentMedian overall survivalRate of complicationsAssociated with higher ratesAntifungal prophylaxisIsavuconazoleFungal infectionsVoriconazoleRetrospective analysisSide effectsPatientsLeukemiaHigher RatesSurvivalNeutropeniaProphylaxisAzoleEarly discharge program cost savings for patients with newly diagnosed acute myeloid leukemia after intensive induction chemotherapy
Hunter C, Chetlapalli K, Ito S, Bewersdorf J, Boddu P, Browning S, Halene S, Parker T, Huntington S, Kothari S, Mendez L, Neparidze N, Sethi T, Stahl M, Podoltsev N, Zeidan A, Shallis R, Goshua G. Early discharge program cost savings for patients with newly diagnosed acute myeloid leukemia after intensive induction chemotherapy. Blood 2025, 146: 6208. DOI: 10.1182/blood-2025-6208.Peer-Reviewed Original ResearchConceptsEarly discharge programAbsolute neutrophil countLow absolute neutrophil countAcute myeloid leukemiaNext therapyIntensive chemotherapyTraditional cohortDirect costsHospital dischargeMyeloid leukemiaDirect costs of careOutpatient clinical careLonger hospitalInpatient bed usePatient's absolute neutrophil countDays of antimicrobial therapyCohort of consecutive patientsCost of careRed blood cell transfusionProgram cost savingsAssociated with longer hospitalSecond-line therapyBlood cell transfusionKaplan-Meier methodRisk exposure period
Academic Achievements & Community Involvement
Copy Link
Activities
activity National Comprehensive Cancer Network (NCCN) - Myelodysplastic Syndromes Guideline Panel
12/01/2020 - PresentCommitteesMemberactivity Older Adult AML Working Group - National Cancer Institute (NCI) Myeloid Precision Medicine Initiative
09/01/2020 - PresentPeer Review Groups and Grant Study SectionsMemberactivity ECOG-ACRIN Leukemia Committee
07/23/2020 - PresentCommitteesMemberactivity American Society of Hematology (ASH)
07/03/2017 - PresentProfessional OrganizationsMemberactivity American Society of Clinical Oncology (ASCO)
07/03/2017 - PresentProfessional OrganizationsMember
Honors
honor Top Overall Abstract
06/08/2020Regional AwardMyeloid Malignancies SymposiumDetailsUnited Stateshonor Hematology/Oncology Fellowship Program Research Award
06/01/2019Yale School of Medicine AwardYale Cancer CenterDetailsUnited States
News
Copy Link
News
- December 13, 2024Source: OncLive
How Luspatercept Could Shake Up MDS Management—With Rory Shallis, MD
- November 26, 2024
Yale Cancer Center to Highlight Breakthroughs in Blood Cancers and Disorders at World’s Largest Hematology Meeting
- May 01, 2024
Yale Department of Internal Medicine Faculty Promotions and Appointments (May 2024)
- March 25, 2024
Yale’s Post ASH Review
Get In Touch
Copy Link